I 

117TH CONGRESS 

1ST SESSION H. R. 1686 

To direct the Comptroller General of the United States to evaluate and 

report on the inpatient and outpatient treatment capacity, availability, 

and needs of the United States. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 9, 2021 

Mr. FOSTER introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on 

Natural Resources, for a period to be subsequently determined by the 

Speaker, in each case for consideration of such provisions as fall within 

the jurisdiction of the committee concerned 

A BILL 

To direct the Comptroller General of the United States to 

evaluate and report on the inpatient and outpatient 

treatment capacity, availability, and needs of the United 

States. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Examining Opioid 

5 Treatment Infrastructure Act of 2021’’. 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 1686 IH

1 SEC. 2. STUDY ON TREATMENT INFRASTRUCTURE. 

2 Not later than 24 months after the date of enactment 

3 of this Act, the Comptroller General of the United States 

4 shall initiate an evaluation of, and submit to Congress a 

5 report on, the inpatient and outpatient treatment capacity, 

6 availability, and needs of the United States, including, to 

7 the extent data are available— 

8 (1) the capacity of acute residential or inpatient 

9 detoxification programs; 

10 (2) the capacity of inpatient clinical stabiliza11 tion programs, transitional residential support serv12 ices, and residential rehabilitation programs; 

13 (3) the capacity of demographic specific resi14 dential or inpatient treatment programs, such as 

15 those designed for pregnant women or adolescents; 

16 (4) geographical differences of the availability 

17 of residential and outpatient treatment and recovery 

18 options for substance use disorders across the con19 tinuum of care; 

20 (5) the availability of residential and outpatient 

21 treatment programs that offer treatment options 

22 based on reliable scientific evidence of efficacy for 

23 the treatment of substance use disorders, including 

24 the use of Food and Drug Administration-approved 

25 medicines and evidence-based nonpharmacological 

26 therapies; 


kjohnson on DSK79L0C42PROD with BILLS
3 

•HR 1686 IH

1 (6) the number of patients in residential and 

2 specialty outpatient treatment services for substance 

3 use disorders; 

4 (7) an assessment of the need for residential 

5 and outpatient treatment for substance use disorders 

6 across the continuum of care; 

7 (8) the availability of residential and outpatient 

8 treatment programs to American Indians and Alaska 

9 Natives through an Indian health program (as de10 fined by section 4 of the Indian Health Care Im11 provement Act (25 U.S.C. 1603)); and 

12 (9) the barriers (including technological bar13 riers) at the Federal, State, and local levels to real14 time reporting of de-identified information on drug 

15 overdoses and ways to overcome such barriers. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS